Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

Merlintrader’s Daily Briefing

Tuesday, August 18, 2026, an end-of-day wrap written from Europe. European trading has closed and the New York session is still running, so the American figures below are readings taken around 2:00 p.m. Eastern time and are not closing prices. The tape split cleanly in two: a bond market that will not settle and Brent at $91 pushed money out of semiconductors and into defense and energy inside the same session.

Where the American session stands
  • The index trackers — With roughly two hours of trading left, $SPY was down 0.65% at $767.63 and $QQQ down 1.74% at $717.15. The Dow tracker $DIA was the mildest of the group at 0.24% lower, and the Russell 2000 fund $IWM was down 1.24%. The spread between the Dow and the Nasdaq is the whole story of the day.Equities
  • Volatility and the dollar — The move was orderly rather than panicked: the VIX futures fund $VIXY was up 0.43% and the dollar tracker $UUP up 0.09%. A one-day drawdown concentrated in a single sector does not usually move the volatility complex much, and it did not.Risk
  • Europe closed first — The Euro Stoxx 50 ended the European session near 6,493 points, about 0.57% lower, extending Monday’s soft finish. Energy prices and the global move in yields were the same two pressures on both sides of the Atlantic.Europe
Semiconductors took the whole loss
  • The sector fund — $SMH was down 4.78% at $565.69, a single-day move large enough to account for most of the Nasdaq’s decline on its own. $INTC was down 7.38% at $95.85 on more than 75 million shares, $AMD down 5.77% at $476.79, $AVGO down 3.06% and $NVDA down 2.31% at $219.81.Semis
  • What changed — No company-specific news explained the size of it. Barron’s framed the session as a pullback arriving days after chip stocks entered a new bull market, and Bloomberg reported a Bank of America note arguing Nvidia trades at a discount of up to 50% once AI risks are priced. Higher long-end yields cut the present value of profits dated far into the future, and the AI complex is the longest-duration equity trade on the board.Semis
  • The rest of the AI chain — The damage was not uniform. $PLTR held a 0.30% gain, $IONQ was down 4.33% and $BBAI down 1.56%. Away from the listed names, Bloomberg reported Anthropic is arranging a credit facility of more than $10 billion ahead of a planned public debut, another sign that AI capacity is now being financed with borrowed money rather than cash flow.AI
Oil, Iran and the long end of the curve
  • The barrel — Brent futures reached $91 and West Texas Intermediate $84, the highest in more than two weeks, after President Trump said he intends to increase economic pressure on Iran and threatened Oman over the Strait of Hormuz. The U.S. Strategic Petroleum Reserve has fallen to its lowest level since 1982, which removes the shock absorber that used to cap moves like this one.Energy
  • The thirty-year — The 30-year Treasury yield touched 5.31% on Monday and traded above that level on Tuesday, a 19-year high, while the 10-year reached 4.72%. The move is global rather than American, and it is being read as a repricing of inflation and government borrowing rather than of Federal Reserve policy.Rates
  • Metals went the other way — Gold and silver, which usually rise with geopolitical risk, did not. $GLD was down 1.53% and $SLV down 3.37%. When the real yield on a thirty-year bond climbs, the asset that pays no coupon is the one that pays for it.Commodities
Defense and energy were the other side of the trade
  • Primes bid — $NOC was up 4.19% at $594.10 and $LMT up 2.94% at $611.19, with $RTX up 1.16%. The sector fund $ITA gained only 0.26%, which says the buying was concentrated in the missile and interceptor names rather than spread across aerospace.Defense
  • Oil equities followed the barrel — $XLE was up 1.54%, $XOM up 2.33% and $CVX up 1.30%. Natural gas moved too, with $UNG up 1.88%.Energy
  • Small caps did not participate — The risk-off tone hit the speculative end hardest. $ASTS was down 5.96%, $RKLB down 3.39%, $LUNR down 2.99% and $RDW down 2.68%. Uranium fell with them: $URA down 3.93%, $OKLO down 5.90%, $LEU down 5.01% and $CCJ down 3.38%. In critical minerals, $MP was down 3.03% and $USAR down 2.88%.Small caps
Biotechnology: large caps up, a regulatory clock at four days
  • The split inside healthcare — The large-cap fund $IBB was up 0.81% while the equal-weighted $XBI was down 0.18%, and the gap was the day’s message: $GILD up 3.16%, $VRTX up 2.72%, $BIIB up 1.84%, $REGN up 1.82% and $AMGN up 1.72%, against $MRNA down 1.35% and $ARWR down 2.39%. Balance sheets were bought, cash burn was not.Biotech
  • $CAPR into its PDUFA — Capricor Therapeutics was down 7.02% at $6.93 with four days left before the August 22 target action date for deramiocel in Duchenne cardiomyopathy. The FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 9 to 3 on July 29 that the evidence does not establish substantial effectiveness, citing the handling of missing data. The committee vote is not binding on the agency, and the date remains the date.FDA
  • Deals kept moving — BioMarin $BMRN rose on an Alesta transaction worth up to $490 million, and $IBRX was down 3.47% on no company news. Merger activity in mid-cap biotech has continued through a week in which the macro backdrop did most of the talking.Biotech
Cannabis: the hostile bid is formally on the table
  • Curaleaf and $ACB — Curaleaf Holdings formally launched its unsolicited takeover bid for Aurora Cannabis on Tuesday, a week after announcing the proposal. Aurora holders would receive 0.3463 Curaleaf shares plus 75 cents in cash per share, total consideration of $4 per share and capped at $5 if Curaleaf stock rises above a set level, valuing Aurora at roughly $260 million. The offer runs until December 1 and needs more than half of Aurora’s independent shareholders. Aurora formed a special committee last week. $ACB was up 1.11% at $3.64, well below the offer price, which is what the market normally does when it doubts a deal closes on those terms.M&A
What the rest of the week turns on
  • Tonight and tomorrow — Toll Brothers $TOL reports after the close, having traded down 2.35% into the print, and Home Depot $HD held a 0.18% gain after reporting this morning. The housing pair is the cleanest read available on what a 30-year yield above 5% does to demand.Earnings
  • The regulatory and earnings calendar — The $CAPR decision is set for August 22 and Zymeworks has an August 25 target date for zanidatamab. Nvidia $NVDA is scheduled to report on August 26 according to the market calendar, which is the event most likely to settle the argument the semiconductor tape started today.Calendar
  • What we could not confirm — The American numbers above are intraday and will change by the close. No company announcement was found that accounts for the size of the move in $NOC and $LMT, so it is described here as sector positioning rather than attributed to a specific catalyst.Method
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 18 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open; one newly resolved catalyst is retained for continuity. October and later events are excluded from this widget.

29On board
16FDA / Reg
13Data / Filing
Aug 18Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXP KETAFREE Ongoing FDA review First-cycle review complete; manufacturer vial attestation submitted

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the ANDA remains active. On August 7, NRx reported that FDA completed its first-cycle review of the preservative-free intravenous ketamine ANDA with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related review matters. The sole remaining major deficiency involved the container-closure system and a manufacturer attestation concerning the luer-lock vial. The same vial is used in three approved ANDA products that collectively shipped 11.9 million units in the United States over the prior 12 months, while the KETAFREE filing included testing of more than 3,500 vials from seven manufactured lots without observed luer-lock failures. On August 17, NRx confirmed that the requested manufacturer attestation had been submitted to FDA. No new exact action date has been disclosed.

$REGN garetosmab Aug BLA Priority Review in adult FOP

Regeneron. The BLA for garetosmab in adults with fibrodysplasia ossificans progressiva remains under Priority Review. Regeneron continues to guide to an FDA decision in August 2026 without disclosing an exact day.

$CAPR deramiocel Aug 22* Extension expected BLA remains active; new 24-month data amendment planned

Capricor. The resubmitted deramiocel BLA remains under FDA review following the July 29 advisory committee vote of 9–3 against the sufficiency of the efficacy evidence for DMD-associated cardiomyopathy. Capricor subsequently said it plans to submit a BLA amendment incorporating 24-month HOPE-3 open-label-extension data and additional analyses focused on upper-limb function. The company has said FDA is willing to review the new information and that the August 22 deadline will be extended after the amendment is received. Until FDA or Capricor formally announces the revised action date, August 22 remains the last published PDUFA date but should no longer be treated as a fixed final-decision deadline.

$RARE DTX401 Aug 23 BLA Gene therapy for GSDIa

Ultragenyx. Priority Review PDUFA for the DTX401 (pariglasgene brecaparvovec) BLA in glycogen storage disease type Ia. The company reaffirmed the August 23 date in its August 4 update.

$JAZZ Ziihera combo Aug 25 sBLA First-line HER2-positive GEA

Jazz Pharmaceuticals. Priority Review PDUFA for the Ziihera (zanidatamab-hrii) sBLA in combination with chemotherapy, with or without tislelizumab, for first-line locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

$GILD BIC/LEN Aug 27 NDA Once-daily oral HIV regimen

Gilead. Priority Review PDUFA for the bictegravir 75 mg/lenacapavir 50 mg NDA, a once-daily single-tablet regimen for virologically suppressed adults with HIV. This is a strategic lifecycle catalyst for the HIV franchise.

$PTGX rusfertide Aug NDA Priority Review in polycythemia vera

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review with a publicly disclosed August 2026 PDUFA goal month. Because no independently verifiable exact day has been published, this board shows the month only.

$TLX Pixclara Sep 11 PDUFA FDA decision on the resubmitted Pixclara NDA

Telix Pharmaceuticals. September 11, 2026 is the FDA PDUFA goal date for the resubmitted Pixclara (TLX101-Px) NDA. The application has already been submitted and accepted for review; the September catalyst is therefore the FDA decision on that NDA, not the NDA filing itself. Pixclara is a PET imaging agent intended to help characterize suspected recurrent or progressive glioma versus treatment-related changes.

$RARE UX111 Sep 19 BLA Gene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A. The company reaffirmed September 19 in its August 4 update; the application seeks accelerated approval.

$MRK WINREVAIR Sep 21 sBLA PAH · HYPERION-based label update

Merck. PDUFA for an sBLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. Merck reaffirmed the September 21 date with its second-quarter results.

$IONS zilganersen Sep 22 NDA Alexander disease

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. It remains one of September’s most closely watched rare-disease regulatory catalysts.

$GRAL Galleri Sep 23 FDA panel AdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel will meet on September 23 to discuss and vote on the Galleri premarket approval application. Galleri is a blood-based multi-cancer early detection test proposed for screening adults aged 50 and older. This is not a drug PDUFA; it is a device and diagnostics regulatory catalyst that is nevertheless material to the stock.

$MIRM zilurgisertib Sep 26 NDA FOP · patients aged 12 and older

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 years and older. Mirum holds exclusive worldwide rights under license from Incyte.

$BFRI Ameluz PDT Sep 28 sNDA Expansion into superficial BCC

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. FDA completed its filing review without identifying filing deficiencies and assigned September 28 as the target action date.

$SRRK apitegromab Sep 30 BLA SMA · review continues with second fill-finish site

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 7, the company said that, in coordination with FDA, Catalent Indiana is being removed from the BLA and review is continuing using the second fill-finish facility; the related data package is under review. CMC and manufacturing risk therefore remain central, while the company continues to state that the action date is unchanged.

$ROIV brepocitinib Q3 NDA Dermatomyositis · Priority Review

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The company has disclosed a PDUFA target action date in the third quarter of 2026 and, if approved, has pointed to a possible U.S. launch around the end of September. No exact PDUFA day has been made public.

$QURE AMT-130 Q3 BLA Accelerated-approval BLA filing in Huntington’s disease

uniQure. The company is preparing an AMT-130 BLA in Huntington’s disease after alignment with FDA on a pathway that may use comparison with an external control as the primary basis of the application. The submission remains a Q3 2026 catalyst; it is not a PDUFA, and FDA filing acceptance would be the next formal step.

$IMMX NXC-201 Late Sep Data NEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026. The program is designed as BLA-enabling/registrational, and subsequent follow-up is expected to contribute to the regulatory path.

$KPTI selinexor combo Aug sNDA Selinexor + ruxolitinib filing in myelofibrosis

Karyopharm. The former XPORT-EC-042 endometrial-cancer catalyst is resolved: on July 30, the study did not meet its primary progression-free-survival endpoint. The active event is now the sNDA the company plans to submit in August for selinexor combined with ruxolitinib in myelofibrosis, with a request for Priority Review.

$KOD DAYBREAK Sep Phase 3 Wet AMD · Zenkuda and KSI-501

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel against aflibercept.

$ALMS envudeucitinib Q3 Data LUMUS Phase 2b in SLE

Alumis. Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter. For an autoimmune readout, the market will assess not only statistical significance but also dose consistency, clinical endpoints and the safety profile.

$IVVD VYD2311 Late Q3 Data DECLARATION pivotal study

Invivyd. Topline data from the pivotal DECLARATION study of VYD2311 are expected approximately toward the end of the third quarter of 2026. The timing remains company guidance rather than a calendar-specific date.

$AMLX avexitide Aug 18 Positive LUCIDITY meets primary endpoint and all secondary endpoints

Amylyx. On August 18, 2026, Amylyx announced positive topline results from the pivotal Phase 3 LUCIDITY trial of avexitide in 78 participants with post-bariatric hypoglycemia. LUCIDITY met the FDA-agreed-upon primary endpoint, with avexitide producing a 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events (p=0.000003). The study also met all secondary endpoints, with consistent and highly statistically significant reductions across additional measures of Level 2 and Level 3 hypoglycemia. Avexitide was generally well tolerated. Amylyx plans to submit an NDA by the end of 2026. This is the single newly resolved catalyst retained in the August 18 board.

$PHVS deucrictibant XR Q3 Phase 3 CHAPTER-3 · HAE prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis remain expected in the third quarter of 2026. This is one of the quarter’s most important registrational HAE readouts.

$SYRE SPY003 Sep Data SKYLINE Phase 2 in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study are expected in September 2026. The company has now specified September rather than only the broader third-quarter window; no exact day has been disclosed.

$VERA TRUTAKNA / atacicept Q3 eGFR ORIGIN 3 confirmatory follow-up

Vera Therapeutics. The ORIGIN 3 eGFR analysis is expected in the third quarter following accelerated approval of atacicept. This is not another approval decision; its significance lies in the durability of the renal effect and the read-through for the confirmatory pathway.

$XENE azetukalner Q3 NDA Focal-onset seizure filing

Xenon. The azetukalner NDA submission in focal-onset seizures remains on track for the third quarter. Filing confirmation would begin FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIO infigratinib Aug 10 NDA submitted Achondroplasia · FDA filing acceptance now becomes the next step

BridgeBio. BridgeBio confirmed on August 10, 2026 that it had submitted the NDA for oral infigratinib in achondroplasia to FDA. The former Q3 “submission” catalyst has therefore occurred. The program remains on the board because the regulatory process is materially open: FDA filing acceptance and any subsequent PDUFA assignment are now the next formal milestones. Infigratinib has Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations in the United States.

$MLTX sonelokimab Late Sep BLA Hidradenitis suppurativa filing

MoonLake. The sonelokimab BLA submission in hidradenitis suppurativa is expected around the end of September 2026. FDA filing acceptance would create the next formal regulatory event.

Most attention-worthy watchlist

$NRXP $CAPR $RARE $PTGX $IONS $GRAL $MIRM $SRRK $PHVS $QURE $IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown, with one newly resolved event retained for continuity. $AMLX/LUCIDITY is the resolved event kept in the August 18 update after the Phase 3 trial met its primary endpoint and all secondary endpoints. $EYPT/LUGANO has been removed after EyePoint reported the readout on August 17; the full dataset did not meet the primary BCVA noninferiority endpoint, although an ad hoc analysis excluding nine patients supported noninferiority and several secondary measures were favorable. $TENX/LEVEL has been removed after the August 10 Phase 3 readout failed both the primary 6MWD endpoint and the key KCCQ-TSS secondary endpoint. $SLN/SANRECO has been removed after the August 10 positive Phase 2 results. $BMY/iberdomide has been removed after FDA granted accelerated approval to ZENBEXUS on August 13. $LNTH/TAUKLARIFY, approved on August 14, has also rolled off the board. $CLNN has been removed because Clene moved the planned CNM-Au8 ALS NDA submission to early Q4 2026, outside this widget. $NRXP remains because the requested manufacturer vial attestation has now been submitted to FDA but no new exact action date has been disclosed. $CAPR remains because the BLA review is still open and a new-data amendment is expected to extend the August 22 deadline. $BBIO remains because the infigratinib NDA was submitted on August 10 and filing acceptance is now the next formal regulatory milestone. For $SYRE, company guidance now specifies September 2026 for SPY003. Month-only and quarter-only windows reflect disclosed guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.